Cover Image
Market Research Report

Global Diabetic Nephropathy Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 298333
Published Content info 98 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Diabetic Nephropathy Market 2018-2022
Published: December 5, 2018 Content info: 98 Pages
Description

About this market

Rise in incidence of diabetes to push growth in the market. Globally, there has been a rise in the incidence and prevalence of diabetes, which has resulted in the occurrence of chronic kidney disease in patients. Technavio's analysts have predicted that the diabetic nephropathy market will register a CAGR of almost 34% by 2022.

Market Overview

Increasing incidence of diabetic nephropathy among diabetic patients

The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type 2 diabetes patients. The factors associated with the rise of incidence of nephropathy are hypertension, hypercholesterolemia, and obesity.

Growing economic burden of diabetic nephropathy

Diabetic nephropathy is a complication associated with diabetes mellitus. The cost associated with diabetic nephropathy increases gradually with the progression of disease due to the associated cost drivers such as dialysis and hospitalization.

For the detailed list of factors that will drive and challenge the growth of the diabetic nephropathy market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Techman-Head Group and Brackett Aircraft Company the competitive environment is quite intense. Factors such as the increasing incidence of diabetic nephropathy among diabetic patients and the rise in incidence of diabetes, will provide considerable growth opportunities to diabetic nephropathy manufactures. AstraZeneca, Merck, and Sanofi are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR23668

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY DRUG CLASS

  • Segmentation by drug class
  • Comparison by drug class
  • ARBs - Market size and forecast 2017-2022
  • ACE inhibitors - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by drug class

PART 09: MARKET SEGMENTATION BY TYPE OF DISEASE

  • Segmentation by type of disease

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Rise in incidence of diabetes
  • Increase in diabetic nephropathy-related cardiovascular mortality and end-stage renal disease
  • Multidisciplinary approach for the management of diabetic nephropathy

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Merck
  • Sanofi

PART 17: APPENDIX

  • List of abbreviations
  • Exhibit 01: Parent market
  • Exhibit 02: Global metabolic disorder drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline drugs for diabetic nephropathy under Phase III stage of development
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Drug class - Market share 2017-2022 (%)
  • Exhibit 19: Comparison by drug class
  • Exhibit 20: ARBs - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 21: ARBs - Year-over-year growth 2018-2022 (%)
  • Exhibit 22: ACE inhibitors - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 23: ACE inhibitors - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Others - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by drug class
  • Exhibit 27: Customer landscape
  • Exhibit 28: Global - Market share by geography 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Top 3 countries in Americas
  • Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in EMEA
  • Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in APAC
  • Exhibit 39: Market opportunity
  • Exhibit 40: Pipeline drugs in various stages of clinical trials for diabetic nephropathy
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: AstraZeneca - Overview
  • Exhibit 47: AstraZeneca - Business segments
  • Exhibit 48: AstraZeneca - Organizational developments
  • Exhibit 49: AstraZeneca - Geographic focus
  • Exhibit 50: AstraZeneca - Key offerings
  • Exhibit 51: Merck - Overview
  • Exhibit 52: Merck - Business segments
  • Exhibit 53: Merck - Organizational developments
  • Exhibit 54: Merck- Geographic focus
  • Exhibit 55: Merck - Segment focus
  • Exhibit 56: Merck - Key offerings
  • Exhibit 57: Sanofi - Overview
  • Exhibit 58: Sanofi - Business segments
  • Exhibit 59: Sanofi - Organizational developments
  • Exhibit 60: Sanofi - Geographic focus
  • Exhibit 61: Sanofi - Segment focus
  • Exhibit 62: Sanofi - Key offerings
Back to Top